FDA Approves BUPRENORPHINE — Actavis Pharma, Inc.

Actavis Pharma has received approval for the ANDA090819 filing, expanding its portfolio with this generic sublingual buprenorphine HCl product, a formulation expected to bolster its presence in the narcotic dependence treatment market while driving revenue through authorized generic pricing.